Delayed London S.E. 5-day change 1st Jan Change
- GBX -.--% Intraday chart for hVIVO plc +18.92% +41.94%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Hvivo Completes Secondary Placing MT
Hvivo Shareholders Plan Secondary Placing to Sell 14 Million Shares MT
Hvivo Wins GBP6 Million Antiviral Testing Contract MT
Hvivo Secures GBP17 Million Contract for RSV Antiviral Drug Testing; Stock Surges MT
Earnings Flash (HVO.L) HVIVO Reports H1 Revenue GBP27.3M MT
Earnings Flash (HVO.L) HVIVO Posts H1 EPS GBX0.58 MT
HVIVO Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Lab Services Company Hvivo to Build New London Facility MT
HVIVO plc Plans for A New Facility to Meet Growing Demand CI
Hvivo Wins GBP13 Million Contract from Global Pharma Client MT
HVIVO Surges 10% on GBP7 Million RSV Drug Testing Contract With Asian Pacific Drugmaker MT
UK's hVIVO Signs GBP2.5 Million Contract for RSV Vaccine Candidate Testing MT
HVIVO Up 9% With $16 Million Antiviral Testing Contract MT
HVIVO Announces £10.4 Million Contract with Existing Big Pharma Client CI
Cocrystal Pharma Engages hVIVO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344 CI
HVIVO Limited Signs £6.2 Million Influenza Human Challenge Study Contract CI
Hvivo Signs £7.2 Million Contract with an Existing Top 5 Global Pharmaceutical Company to Test Its Orally Administered Antiviral Product CI
HVIVO Signs GBP 14.7 Million Influenza Contract CI
HVIVO Signs a £7.3 Million Influenza Human Challenge Study Contract Win CI
HVIVO Receives New Study with an Existing Big Pharma Client to Act as A Vaccination Site for A Phase II Field Study CI
HVIVO Signs Substantial Contract with an Existing Top 5 Global Pharmaceutical Client to Manufacture Virus for Use in Human Challenge Studies CI
HVIVO Wins £5 million RSV Human Challenge Study Contract CI
HVIVO Announces Positive Results from RSV Human Challenge Study CI
HVIVO Signs £5 Million Influenza Human Challenge Study Contract with a Biotech Company CI
Hvivo Limited Signs $13.4 Million Contract with A US-Based Biotechnology Company to Test Its Novel Antiviral Candidate Using the Hvivo Influenza Human Challenge Study Model CI
Chart hVIVO plc
More charts
hVIVO plc, formerly Retroscreen Virology Group plc, is a holding company. The Company is engaged in a life sciences business pioneering a technology platform of human disease models to accelerate drug discovery and development in respiratory and infectious diseases, including flu, respiratory syncytial virus (RSV), asthma and common cold. It has commercialized approximately four disease models, enrolled over 2,000 subjects and conducted approximately 40 product validation studies for a range of industry, government and academic clients and collaborators. The Company offers services, such as challenge study services, lab services, and target and biomarker discovery. It offers viral challenge studies in healthy volunteers in influenza, human rhinovirus (HRV) and RSV. Its lab services include assay development, transfer and optimization across the immunological, molecular and cell-based assay platforms, including offering options in sample matrix testing and specialty biomarker assays.
More about the company
  1. Stock Market
  2. Equities
  3. HVO Stock
  4. News hVIVO plc
  5. HVIVO Surges 10% on GBP7 Million RSV Drug Testing Contract With Asian Pacific Drugmaker